Opus Genetics (IRD) Equity Average (2011 - 2026)

Opus Genetics (IRD) has 16 years of Equity Average data on file, last reported at -$15.2 million in Q1 2026.

• Quarterly Equity Average fell 358.44% year-over-year to -$15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.2 million (down 358.44% YoY) and the FY2025 annual result came in at $11.0 million, down 61.02% from the prior year.
• Equity Average retreated to -$15.2 million in Q1 2026 per IRD's latest filing, from $10.7 million in the prior quarter.
• Across five years, Equity Average topped out at $50.1 million in Q4 2023 and bottomed at -$15.2 million in Q1 2026.
• The 5-year median for Equity Average is $20.5 million (2024), against an average of $25.2 million.
• The widest annual swing landed in 2022, when Equity Average soared 1181.73%; it then plunged 358.44% in 2026.
• Tracing IRD's Equity Average over 5 years: stood at $29.1 million in 2022, then soared by 72.39% to $50.1 million in 2023, then sank by 59.05% to $20.5 million in 2024, then slumped by 48.04% to $10.7 million in 2025, then tumbled by 243.04% to -$15.2 million in 2026.
• Per Business Quant, the three latest IRD Equity Average figures stand at -$15.2 million (Q1 2026), $10.7 million (Q4 2025), and $11.7 million (Q3 2025).

Peer Comparison